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Abstract
Background: Dipterinyl calcium pentahydrate (DCP) has previously been shown to inhibit MDA-MB-231 human
breast cancer xenographs in nude mice in a manner correlated with increases in plasma IL-12 and IL-4
concentrations, and decreases in plasma IL-6 levels. DCP also inhibits indoleamine 2,3-dioxygenase (IDO), an
immuno-inhibitory enzyme, in human PBMCs (Peripheral Blood Mononuclear Cells).
Methods: In the present study, DCP was administered per os, once daily for 14 days to hepatitis B virus (HBV)
transgenic mice at 23, 7.3, and 2.3 mg/(kg d). Multivariate stepwise regression and MANOVA analyses, by gender
and treatment, of liver HBV DNA and RNA measures, liver core and serum HBe antigen assays, serum cytokine/
chemokine profiles, and IDO metabolite measurements were performed.
Results: DCP caused a significant dose-response reduction of log liver HBV DNA as measured by PCR in the female
HBV mice. The gender dependence of the anti-HBV DNA activity was explained by the DCP Effects Model (DCP-
EM) (p = .001) which includes three serum biomarker changes caused by DCP: 1) decreased MCP-1; 2) decreased
Kyn/Trp (an estimation of IDO activity); and 3) increased GM-CSF.
Conclusions: Immunomodulation via IDO or TDO (tryptophan 2,3-dioxygenase) pathways, along with serum MCP-
1 and GM-CSF are proposed to play roles in the anti-HBV mechanism of DCP based upon their coordinated
modulation in the reduction of viral DNA replication in HBV mice.
Background
Hepatitis B virus (HBV) causes both transient and per-
sistent infections of the liver in humans. The number of
chronic HBV carriers is estimated to be 400 million
worldwide; nearly 25% of which are projected to suc-
cumb to liver failure or liver cancer [1]. Additionally,
HBV infection remains an important cause of acute and
chronic liver disease in the United States [2]. Dipterinyl
calcium pentahydrate (DCP), shown in Figure 1, has
demonstrated significant antitumor activity associated
with plasma IL-12 concentration increases in MDA-MB-
231 (human breast cancer) xenographs in nude mice
[3,4]. This finding, along with previous work demon-
strating IL-12 suppression of HBV replication in trans-
genic mice [5], prompted us to investigate the activities
of DCP in the HBV transgenic mouse model.
DCP is a stable, sparingly soluble compound that can
be solubilized in aqueous solutions to 440 μMw i t h
sonication. For this study, an orally administered suspen-
sion was used. It was hypothesized that because of the
antitumor changes elicited by DCP, as well as the anti-
and pro-inflammatory plasma cytokine/chemokine con-
centration changes reported previously, DCP would
reduce liver HBV DNA levels and possibly other HBV
parameters in transgenic mice carrying an infectious
clone of HBV. The investigators anticipated that DCP
might work via cytokine/chemokine modulatory mechan-
isms similar to those described by others [5-9].
Evidence for immunomodulation by DCP was further
investigated by measurement and analysis of the enzyme
indoleamine 2,3-dioxygenase (IDO) serum metabolites,
tryptophan (Trp) and kynurenine (Kyn). Tryptophan
(Trp) is the substrate for IDO, a key immunological inhi-
bitor of T cells, and an identified tumor escape mechan-
ism [10]. Recent studies have demonstrated that IDO-
mediated immune suppression is prevalent in hepatitis B
infection [11]. The IDO enzymatic product, kynurenine
(Kyn), and its downstream metabolites, kynurenine,
3-hydroxykynurenine, and 3-hydroxyanthranilic acid, are
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lymphocytic cell types, i.e., NK cells and B cells [12]. We
have shown previously that DCP inhibits IDO activity in
human PBMCs (Peripheral Blood Mononuclear Cells) [3].
Certain neurotoxic end-products of the tryptophan-
kynurenine pathway, such as quinolinic acid, produced
under chronic inflammatory conditions (e.g., cardiovascu-
lar disease, multiple sclerosis, diabetes, cancer, and major
depression) may contribute to the brain damage seen in
depression and dementia [13]. For the study described
here, the calculation of the serum Kyn-to-Trp ratio (Kyn/
Trp) allowed us to estimate the extent of IDO activity in
the serum of the HBV mice [14].
Materials and methods
Materials
Compounds
DCP was suspended in 0.4% carboxymethylcellulose
(CMC) at concentrations sufficient to deliver the desired
dose by oral gavage in a volume of 0.1 mL per 20 g
mouse. The solution was stored at 4°C during the
course of the experiment. The volume was adjusted for
the weight of each mouse. The structure of DCP [3] is
given in Figure 1. The positive control, adefovir dipivoxil
(ADV) (Gilead Pharmaceuticals), was prepared in the
same manner as the DCP for the appropriate dosages.
Methods
In vivo testing
Animals Homozygous adult female and male transgenic
HBV mice were used (20.6 ± 2.8 g). The mice were ori-
ginally obtained from Dr. Frank Chisari (Scripps
Research Institute, La Jolla, CA) [15] and were subse-
quently raised in the Biosafety Level 3 (BL-3) area of the
AAALAC-accredited USU Laboratory Animal Research
Center (LARC). The animals were derived from founder
1.3.32 [15]. This study was conducted in accordance
with the approval of the Institutional Animal Care and
Use Committee of Utah State University.
Experimental design DCP was administered per os,
once daily for 14 days to 94 randomly assigned HBV
transgenic mice at 23 mg/(kg d) (10 females/10 males),
7.3 mg/(kg d) (10 females/10 males), and 2.3 mg/(kg d)
(10 females/10 males). DCP dosages were based upon
previously reported efficacious levels for antitumor
activity [3]. ADV was used as a positive control at
10 mg/(kg d) (10 females/5 males) using the same treat-
ment schedule and vehicle (0.4% CMC). 10 female/9
male control vehicle mice were used. This efficacious
ADV dosage used was previously demonstrated in HBV
mice [9]. On day 14, mice were euthanized to collect
serum and liver samples to perform liver HBV DNA,
liver HBV RNA, liver core and serum HBe antigen
assays, serum cytokine/chemokine profiles, and IDO
metabolite measurements. No plasma level measure-
ments of DCP were performed.
Virology
Liver HBV DNA assays Southern blot hybridization and
quantitative PCR (qPCR) were performed on liver tis-
sues [9]. For Southern blot hybridization, the ratio of
the viral DNA bands to the transgene band was used to
determine the concentration of viral DNA per host
DNA. This calculation was based upon the knowledge
that there were 1.3 copies of the transgene present per
host cell with this line of transgenic mice. The transgene
was used as an internal indicator to calculate the pg of
HBV DNA per μg of homozygous cellular host DNA.
For qPCR, the assay was run with a series of 10-fold
dilutions of pooled liver DNA from HBV transgenic
mice to obtain a standard curve. Mean C(t) values were
obtained for duplicates of each sample. The mean C(t)
values of each sample were used to obtain the log rela-
tive DNA values using a formula of the fit line of the
standard curve.
Liver HBV RNA Liver samples were assayed for HBV
RNA as described previously [9]. The RT-PCR techni-
que used for determining liver HBV DNA (PCR) has
been reported to be more rapid and sensitive, and can
be more specific that northern blot analysis [16].
Liver or serum cytokine/chemokine array Liver
samples were prepared for the Q-Plex™ mouse
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Figure 1 The structure of dipterinyl calcium pentahydrate,
(C6H4N5O)2Ca·5H2O (MW 454.4). The X-ray crystallographic
structure was given previously [3].
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UT) as described previously [9].
Sera HBeAg W h o l eb l o o ds a m p l e sw e r eo b t a i n e dd u r -
ing necropsy by cardiac puncture, and processed for
HBeAg-specific ELISA (International Immuno Diagnos-
tics, Foster City CA) [9]. Using the known PEI (Paul
Ehrlich Institute) units for the calibrator, PEI units were
formulated for the serial dilutions of the positive serum.
A graph was generated, and extrapolation was used to
assign a PEI unit value for each sample.
Liver HBcAg assay Liver biopsies were processed for
detection of hepatitis B core antigen (HBcAg) [9]. Three
different parameters were obtained from each tissue sec-
tion. The first two measurements were based on the
observation that cells surrounding the central veins of
the liver are more strongly stained than are other areas
of the liver (personal observation). The first two para-
meters were obtained by counting cells surrounding
central veins as follows: the total number of cells, the
number of cells with stained nuclei, and the number of
cells with stained cytoplasms. The identities of the sam-
ples were blinded to the person counting. The stained
nuclei counts or the stained cytoplasm counts were
divided by the total number of cells. Three central vein
areas were counted for each slide sample. For the third
parameter, a field not in a central vein area was counted
f o rt h et o t a ln u m b e ro fs t a i n e dn u c l e i .O n e - q u a r t e ro f
the field was counted. Three such fields were counted
per liver section. The identities of the samples were
blind to the person reading the slides.
Tryptophan and kynurenine measurements Serum
tryptophan (Trp) and kynurenine (Kyn) measurements
were carried out as previously described [17]. Kyn/Trp
ratios were calculated for each mouse as an estimate of
IDO activity.
Statistical analysis
Those measures found to be significant by the Kruskal-
Wallis nonparametric test for treatment group effects
were then tested by one-way ANOVA, followed by
post-hoc 2-sided Dunnett tests (for equal variances) or
Dunnett’s T3 tests (for unequal variances) versus con-
trols. The Mann-Whitney U nonparametric test was
used to test gender effects, followed by one-way
ANOVA. A 2-way MANOVA was carried out to test
gender-treatment interactions. Multivariate stepwise
regression analysis was performed on the full data set,
along with six log transformed DNA and RNA vari-
ables, to identify a significant, small-number cluster of
variables modeling DCP dosage from the larger num-
ber of variables measured. SPSS Graduate Pack 15.0 for
Windows (2006) was utilized with p <. 0 5u s e dt o
determine significance.
Results
The following viral, IDO, and cytokine/chemokine mea-
sures were collected in this study: liver HBV DNA
(Southern), liver HBV DNA (PCR), liver HBV RNA
(PCR), HBe antigen (ELISA); Average # HBcAg Nuclei,
Average # HBcAg Cytoplasms, # HBcAg Nuclei per
Quarter Field; serum Tryptophan, Kynurenine, Kyn/Trp,
IL-1a, IL-1b, IL-2, IL-3, IL-4,I L - 6 ,I L - 9 ,I L - 1 0 ,I L - 1 2 ,
MCP-1, TNF-a,M I P - 1 ,G M - C S F ,R A N T E S ;a n dl i v e r
IL-6. See additional file 1: “Summary Statistics” for the
data summary and statistical results from this study.
Table 1, Table 2 gives the derivation of the significant
(p = .001) DCP Effects Model (DCP-EM) variable cluster
from the linear multivariate stepwise regression of DCP
dosage versus all the viral, IDO, and cytokine/chemo-
kine measures. The logarithmically transformed liver
HBV DNA (Southern), liver HBV DNA (PCR), liver
HBV RNA (PCR), and HBe antigen (ELISA) measures
were included in this analysis as in previous studies
[9,18,19]. The DCP Effects Model linear stepwise regres-
sion analysis identified a significant (p = .001) cluster of
variables responding to the DCP treatment. Stepwise
regression analyses, in general, derive a small cluster of
variables from a much larger set of variables in order to
model a particular variable of interest, in the present
study, the DCP dose. Taken individually, the component
variables of a derived cluster do not achieve the same
level of significance as the cluster taken as a whole. In
the present study, Log liver HBV DNA (PCR) emerged
a st h es i n g l es t r o n g e s tv i r a lv a r i a b l ew h i c hs i g n i f i c a n t l y
and inversely modeled DCP dosage. None of the other
viral measures significantly further explained the DCP
dosage variance. These other viral measures included: 1)
liver HBV DNA (Southern), 2) liver HBV DNA (PCR),
3) liver HBV RNA (PCR), 4) the log liver HBV DNA
(Southern), and 5) log liver HBV RNA (PCR). The DCP
Effects Model regression, however, identified the serum
measures Kyn/Trp, MCP-1, and GM-CSF as significant
additional variables which further accounted for DCP
dosage variance (Table 1, Table 2).
The molecular biology of HBV RNA synthesis, which
was not affected by any of the treatments in the HBV
transgenic mice, is significantly different from that of
the natural HBV infection.
The HBV RNA in the transgenic mice is produced
primarily from an HBV transgene, unlike a natural
infection wherein it is expressed from HBV covalently
closed circular DNA (cccDNA) (Raney et al., 2001) [20].
Unlike the natural infection, HBV produced from the
transgene in mice cannot infect mouse cells for succes-
sive rounds of viral replication. In the natural infection,
HBV RNA and HBe and HBs proteins are derived from
successive rounds of replication to produce increasing
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HBV RNA and proteins. In this regard the use of the
HBV transgenic mice is analogous to HBV stably trans-
fected, cells such as Hep G 2.2.15 cells (Iyer et al.,
2004a) [21]. It was not unexpected, therefore, that a
selective reduction of HBV DNA would not necessarily
affect HBV RNA or protein levels, since these levels can
be independently derived from the HBV RNA tran-
scribed from the transgene. [9]
The Figure 2 profile of log rel. liver HBV DNA (PCR)
by treatment shows significant efficacy for the female
mice at 23 mg/(kg d) DCP (p <. 0 5 )a sc o m p a r e dt o
female controls. The figure also shows that log rel. liver
HBV DNA (PCR) is significantly lower than controls for
10 mg/(kg d) adefovir dipivoxil (p < .05) in both sexes.
Moreover, Figure 2 shows that there are significant gen-
der differences in viral DNA levels for all DCP dosage
levels tested. A similar treatment response pattern was
found for the log liver HBV DNA (Southern) measure
(see additional file 1: “Summary Statistics”).
In order to explain the Figure 2 DCP/gender differ-
ences, an ADJUSTED log rel. liver HBV DNA (PCR)
was calculated for each mouse based upon the DCP-EM
regression from Table 1, Table 2, rearranged algebrai-
cally as shown in the legend of Figure 3. The resultant
ADJUSTED log rel. liver HBV DNA (PCR) values
demonstrated no significant gender differences among
the mice for any treatment group. Therefore, the log rel.
liver HBV DNA (PCR) gender differences were
accounted for by adjusting for the Kyn/Trp, MCP-1,
and GM-CSF serum levels for each mouse, as shown in
Table 1 The DCP Effects Model (DCP-EM) was derived from the stepwise regression of the DCP dose versus: serum
Tryptophan, Kynurenine, Kyn/Trp; HBV DNA [Southern], HBV DNA [PCR], HBV RNA [PCR], HBe antigen [ELISA];
Average # Liver HBcAg Nuclei per Total, Average # Liver HBcAg Cytoplasms per Total, Average # Liver HBcAg Nuclei
per Quarter Field; IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-6, IL-9, IL-10, IL-12, MCP-1, TNF-a, MIP-1, GM-CSF, RANTES, and liver
IL-6; log HBV DNA [Southern], log rel. HBV DNA [PCR], log HBV RNA [PCR], and log HBe antigen [ELISA].
Coefficients of variables in cluster modelling DCP dosing effects
Unstandardized Coefficients Standardized Coefficients
DCP-EM Model* (variable cluster) B Std. Error Beta Sig.
(Constant) 26.309 4.976 .000
MCP-1 -.022 .007 -.371 .003
Log HBV DNA (PCR) -4.065 1.376 -.359 .005
Kyn/Trp -.560 .196 -.349 .006
GM-CSF .070 .030 .283 .023
Probability-to-Enter = .10 and Probability-to-Remove = .15. The model is significant to *p = .001.
Derived DCP-EM Regression Model*:
DCP-EM score = 26.309 - 0.22 [MCP-1 rel. pg/ml] - 4.065 [Log rel. HBV DNA (PCR)]
-.560 [Kyn/Trp uM/mM] + 0.070 [GM-CSF rel. pg/ml]
Table 2 Excluded variables not included in DCP-EM
model
Model Beta
In
Sig. Partial
Correlation
Trp .097 .453 .100
Kyn -.008 .977 -.004
HBV DNA (Southern) -.013 .932 -.011
HBV DNA (PCR) -.130 .491 -.091
HBV RNA (PCR) -.008 .947 -.009
HBe (ELISA) .187 .184 .175
Ave Liver HBcAg Nuclei per Total .040 .739 .044
Ave Liver HBcAg Cytoplasm per
Total
.100 .399 .112
Ave Liver HBcAg Nuclei per
Quarter Field
-.051 .698 -.052
IL-1a -.073 .531 -.083
IL-1b -.058 .639 -.062
IL-2 -.112 .534 -.083
IL-3 -.112 .336 -.128
IL-4 .157 .175 .179
IL-6 -.128 .282 -.142
IL-9 .043 .718 .048
IL-10 -.089 .447 -.101
IL-12 -.023 .850 -.025
TNF-a -.078 .532 -.083
MIP-1 .047 .690 .053
RANTES .166 .161 .185
Liver IL-6 .057 .626 .065
Log HBV DNA (Southern) .044 .804 .033
Log HBe (ELISA) .178 .176 .178
Log HBV RNA (PCR) -.011 .925 -.012
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(PCR) scores in Figure 3.
Discussion
The significant Table 1, Table 2 linear stepwise regres-
sion quantifies a DCP Effects Model (DCP-EM) for the
HBV mice showing a significant relationship between
the inhibition of hepatitis B DNA replication and DCP
dosage in the context of three serum immunological
changes. The three immunological changes found to be
significantly associated with DCP’s reduction of viral
DNA levels are: 1) decreased MCP-1; 2) decreased Kyn/
Trp (an estimation of IDO activity); and 3) increased
GM-CSF. Among female HBV mice, 23 mg/(kg d) DCP
was found to reduce control values of log rel. HBV
DNA (PCR) to levels comparable to those achieved by
the antiviral agent adefovir dipivoxil (Figure 2). When
serum Kyn/Trp (IDO activity), MCP-1, and GM-CSF
levels were taken into account and ADJUSTED log rel.
liver HBV DNA (PCR) values calculated for each mouse
(Figure 3), gender differences in log rel. HBV DNA
levels vanished, implicating the involvement of these
immunological variables in the gender differences.
Table 1, Table 2 shows that DCP decreases MCP-1
serum levels. MCP-1 (Monocyte chemotactic protein-1)
is a small cytokine belonging to the CC chemokine
family, also known as Chemokine (C-C motif) ligand 2
(CCL2), which recruits monocytes, memory T cells, and
dendritic cells to sites of tissue injury and infection
[22,23]. A number of genetic loci have been proposed to
be associated with persistent hepatitis B virus (HBV)
infection [24], including the MCP-1 -2518 G/G geno-
type and G allele, more frequent in HBV patients than
controls (P < 0.01, after multiple corrections Pc < 0.05).
In other studies with HBV-associated hepatoma cells,
MCP-1 is found to be overexpressed [25]. Table 1,
Table 2 also shows that DCP increases GM-CSF serum
levels. GM-CSF induces the differentiation of granulo-
cyte, macrophage, and eosinophil precursor cells, as
well as the proliferation of monocyte-macrophages,
Figure 2 The Mean Log [relative Liver HBV DNA (PCR)] by treatment group and gender for HBV mice. DCP was administered per os,
once daily for 14 days to 94 randomly assigned HBV transgenic mice at 23 mg/(kg d) (10 females/10 males), 7.3 mg/(kg d) (10 females/10
males), and 2.3 mg/(kg d) (10 females/10 males). ADV was used as a positive control at 10 mg/(kg d) (10 females/5 males) using the same
treatment schedule and vehicle (0.4% CMC). 10 female/9 male control vehicle mice were used. Mean Log [relative Liver HBV DNA (PCR)] values,
as measured by quantitative PCR are graphed by treatment group and gender for HBV mice (ADV = Adefovir dipivoxil). * (p < .05) - Mean Log
[relative liver HBV DNA (PCR)] is significantly different than controls [DCP = 0.0 mg/(kg d) of the same gender] for females at 23.0 mg/(kg d) DCP
and for ADV in both females and males.
#### (p ≤ .001) - Mean Log [relative liver HBV DNA (PCR)] is significantly different by gender.
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CSF is produced by T lymphocytes, macrophages, and
several cell types in extramedullary sites, where it may
act in a paracrine manner to regulate the local response
to antigenic challenge [26]. Clinical trials evaluating the
efficacy and safety of GM-CSF as an adjuvant to hepati-
tis B vaccine in patients with end-stage renal disease
showed improved seroprotection rates with HBV vac-
cine after GM-CSF administration [27]. Therefore,
serum MCP-1 is a HBV risk factor decreased by DCP,
while GM-CSF, whose serum level is increased by DCP,
has been shown to be a effective HBV vaccine adjuvant.
The inhibition of the enzyme IDO by DCP is signifi-
cantly correlated to the decrease of HBV DNA in the
DCP Effects Model (Table 1, Table 2). Notably, the
mean control value for female HBV mouse serum Kyn/
Trp (22.2 ± 2.2 uM/mM) is greater than the mean con-
trol serum Kyn/Trp for male HBV mice (12.8 ± 1.1 uM/
mM). Furthermore, the mean female HBV mouse Kyn/
Trp value is closer in magnitude to normal human
serum Kyn/Trp (26.5 - 45.0 uM/mM) [14,28,29]. These
findings, taken together with the finding that the serum
IDO gender difference for the HBV mice accounts, in
p a r t ,f o rt h eg e n d e rd i f f e r e n c e ss e e ni nt h eF i g u r e2
DCP dose-response diagram, and strongly suggests that
DCP has greater anti-HBV efficacy in female HBV mice
partly because to their elevated serum IDO.
One could argue that the lower IDO activity in males
would render this pathway more susceptible to the
effects of DCP, and that a lower dose of this compound
would be effective in targeting the more limiting IDO
metabolites in male mice. However, since indoleamine
2, 3-dioxygenase (IDO) metabolizes the essential amino
acid tryptophan in mammals, catalyzing the initial and
rate-limiting step in the de novo biosynthesis of nicoti-
namide adenine dinucleotide (NAD) [30], excessively
low levels of IDO, and consequently NAD, would be
debilitating to the male mice. Males likely have meta-
bolic mechanisms to prevent the IDO/NAD pathway
from dropping below basal levels.
Figure 3 The ADJUSTED Log [rel. Liver HBV DNA (PCR)] by treatment group and gender calculated for each HBV mouse. In order to
isolate the effects of DCP treatment away from the effects of the other DCP-EM variables, ADJUSTED Log [rel. Liver HBV DNA (PCR)] values
were calculated for each mouse, based upon the Table 1, Table 2 regression model algebraically rearranged as follows:
ADJUSTEDLog [rel. LiverHBCDNA(PCR)
DCP-EMscore
]
(. ) /

 26 309 4 4 065
0 138 0 054 0
.
[( ) ] . .

  Log rel.LiverHBV DNA PCR Kyn/Trp MCP-1 . .017GM-CSF
The ADJUSTED scores are graphed by treatment group and gender for the HBV mice (ADV = Adefovir dipivoxil). ** (p < .01) - Mean
ADJUSTED Log [rel. Liver HBV DNA (PCR)] is significantly different than controls [DCP = 0.0 mg/(kg d) of the same gender] only for females at
23.0 mg/(kg d) DCP. No significant gender differences were found for any of the treatment groups (p ≥ .095).
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nificantly higher serum IDO activity than the male mice
is biologically relevant to HBV expression in these trans-
genic mice in the following ways. IDO immuno-inhibi-
tion has been found to take two forms, 1) as a depletor
of the nutrient tryptophan, and 2) through the direct
action of its enzymatic products, kynurenine, 3-hydroxy-
kynurenine, and 3-hydroxyanthranilic acid on immune
cells [10,12,14,31,32]. In previous studies, female HBV
mice were identified to have slightly lower levels of liver
and serum HBV DNA than male mice [33,34]. Thus,
these two gender-differentiated measures, liver HBV
DNA levels and IDO activity, might be connected
mechanistically. For example, HBV surface antigens can
be regulated in HBV transgenic mice by sex steroids
and glucocorticoids [35]. Similarly, both IDO, and its
related hepatic enzyme TDO (hepatic tryptophan pyrro-
lase; tryptophan 2,3-dioxygenase) can be upregulated by
steroids like estrogen [36-38]. Therefore, there are links
between the lower levels of liver HBV DNA in female
mice, and hormone-regulated tryptophan metabolism.
Further evidence for a gender-HBV linkage is that hepa-
tocellular carcinoma (HCC), one of the human cancers
etiologically related to HBV, affects males in a signifi-
cantly higher proportion than females [39]. A similar
gender effect is seen in HBV-transgenic C57BL/6 mice
[40]. Also, male gender is a predictor of poor response
to IFN-a treatment of chronic hepatitis B (CHB) [41].
The involvement of IDO activity in determining the
levels of liver HBV DNA can explain the mechanism of
the anti-HBV activity of DCP. Since DCP is known to
inhibit IDO in human PBMCs [3], the higher IDO activ-
ity found in the sera of the female HBV mice allows for
a proportionally greater degree of IDO inhibition by
DCP, and consequently relatively greater immuno-
enhancement, since IDO is a Th1-inhibitory enzyme. A
higher IDO activity in the female HBV mice provides
more metabolic targets for inhibition by DCP, and a
greater de-repression of Th1 immune responses. In
humans, altered IDO-related serum metabolite concen-
trations, i.e., lower tryptophan and kynurenine levels,
have been found in young adult females as compared to
young adult males [42].
The serum IDO differences between humans and mice
might also be related to iNOS differences because 1)
human macrophages are deficient in high output NO
production [43,44], and 2) NO interferes with IDO
expression and function [45]. Thus, the lower serum
Kyn/Trp (i.e., lower IDO activity) in mice as compared
with humans might be due to the higher NO levels in
mice. Further examination of these possible factors
influencing serum IDO is of interest since endogenous
IDO levels are found to play a significant role in the
antiviral activity of the immunomodulator DCP.
DCP inhibition of serum IDO as part of its anti-HBV
effect reduces circulating kynurenine levels, and
increases tryptophan availability, both of which
enhance T cell-, B cell- and NK-mediated immunity
[10,12,14,31,32]. Studies linking the collapse of HBV-
specific CD8 T-cells, and impaired innate immunity
(NK cells) in persons with chronic hepatitis B (CHB)
have been reviewed [46]. HBV-specific CD8
+ Tcells are
associated with viral control (HBV DNA load) [47,48],
and reducing HBV replication to <10
7 copies/ml is sug-
gested to maximize the chances of vaccines to expand a
broad repertoire of HBV-specific CD8
+ cells [48]. Our
data shows that DCP significantly inhibits IDO in the
HBV transgenic mice. Moreover, a number of studies
show a significant positive linkage between IDO and the
PD-1/PD-L1 pathway [49-54]. PD-1 receptors are found
on activated T cells, B cells, macrophages, and DCs [55],
and expansion of the PD-1 pathway by T cells was asso-
ciated with viral replication in a model of chronic HBV
infection [56]. Therefore, a DCP-driven decrease of IDO
activity should, in turn, downgrade the PD-1 pathway,
expand HBV-specific T cells, and lead to a decrease in
HBV DNA. Further study into these connections can
more firmly establish this model.
A recent review of the woodchuck hepatitis virus
model [57] discusses immunotherapeutic approaches
based upon the reconstitution of Th1 immune
responses. IFN-g antiviral immune responses stimulate
IDO activity in a self-limiting manner due to the T cell
inhibitory effects of the IDO-produced kynurenines. By
inhibiting IDO with inhibitors such as DCP, the Th1
type immune response can be enhanced while the
negative effects of kynurenine are decreased. However,
while IDO inhibition probably improves immune func-
tioning, it may also serve to enhance the rate of viral
reproduction due to the inhibition of tryptophan depri-
vation and consequent enhancement of growth condi-
tions. On the other hand, it is also possible that some
of the immunological effects of DCP are due to a gen-
eral growth inhibition that diminishes virus multiplica-
tion. Also, the present study did not measure the
plasma levels of HBV DNA, and the HBs and HBe
antigens, which would be critical for the evaluation of
the effects of DCP upon circulating HBV titers, viral
assembly, and infectivity.
Conclusions
A linear stepwise regression model, the DCP Effects
Model (DCP-EM), was generated from viral and immu-
nological measures collected from hepatitis B virus
(HBV) transgenic mice treated with dipterinyl calcium
pentahydrate (DCP). Three significant serum changes
were found to be associated with the inhibition of HBV
DNA (PCR) replication by DCP. These immunological
Moheno et al. Journal of Translational Medicine 2010, 8:32
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Page 7 of 9changes were: 1) decreased MCP-1; 2) decreased Kyn/
Trp (an estimation of IDO activity); and 3) increased
GM-CSF. Among the female HBV mice, 23 mg/(kg d)
DCP was found to reduce log HBV DNA to levels com-
parable to those achieved by the antiviral agent adefovir
dipivoxil.
Additional file 1: Summary Statistics. The mean and standard error of
each measured variable by treatment and gender.
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